Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma

The development of resistance to trastuzumab in HER2‐positive gastroesophageal cancer remains a problem. The use of dual HER2 blockade to overcome this is a therapeutic strategy that should be researched more extensively.

Detalles Bibliográficos
Autores principales: Cheong, E. Von, Ho, Gwo Fuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077340/
https://www.ncbi.nlm.nih.gov/pubmed/33936677
http://dx.doi.org/10.1002/ccr3.4009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077340/
https://www.ncbi.nlm.nih.gov/pubmed/33936677
http://dx.doi.org/10.1002/ccr3.4009

Ejemplares similares